Merck & Co.

Merck & Co., Inc.
(Merck Sharp & Dohme (MSD) outside the United States and Canada)

Type	Public (NYSE: MRK) Dow Jones Industrial Average component
Industry	Pharmaceuticals
Founded	1891 as a subsidiary of Merck KGaA 1917 as an independent company
Headquarters	Whitehouse Station, New Jersey, United States
Key people	Richard T. Clark, Chairman, President & CEO Stanley F. Barshay, EVP and president, Consumer Health Care Richard S. Bowles, Ph.D., chief compliance officer Willie A. Deese, EVP and president, Merck Manufacturing Kenneth C. Frazier, EVP and president, Global Human Health Mirian Graddick-Weir, Ph.D., EVP, Human Resources Peter N. Kellogg, chief financial officer Peter S. Kim, Ph.D., EVP and president, Merck Research Laboratories Raul E. Kohan, president, Animal Health Bruce N. Kuhlik, general counsel J. Chris Scalet, chief information officer, Global Services Mervyn Turner, Ph.D, chief strategy officer
Products	Gardasil Singulair Propecia/Proscar Zocor Vioxx Fosamax See more complete products listing.
Revenue	US$27.4 Billion (FY 2009)[1]
Operating income	US$4.83 Billion (FY 2009)[1]
Net income	US$12.9 Billion (FY 2009)[1]
Total assets	US$112 Billion (FY 2009)[2]
Total equity	US$59.1 Billion (FY 2009)[2]
Employees	61,500 (2005)
Website	merck.com

Merck & Co., Inc. (NYSE: MRK), also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. It was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and set up as an independent company. It is currently one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue.

Merck & Co. or MSD describes itself as a "a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures." The Merck Company Foundation has distributed over $480 million to educational and non-profit organizations since it was founded in 1957.^[3]

Merck publishes the The Merck Manuals, a series of medical reference books that includes the Merck Manual of Diagnosis and Therapy, the world's best-selling medical textbook, and the Merck Index, a collection of information about chemical compounds.

History

Merck & Co. traces its origins to Friedrich Jacob Merck who purchased a drug store in Darmstadt, Germany in 1668; and Emanuel Merck who took over the store several generations later, in 1816. Emanuel and his successors gradually built up a chemical-pharmaceutical factory that produced — in addition to raw materials for pharmaceutical preparations — a multitude of other chemicals.

In 1891, George Merck established his roots in the United States and set up Merck & Co. in NY as the US arm of the family partnership, E. Merck (named for Emanuel Merck), which is now Merck KGaA. Merck & Co. was confiscated in 1917 during World War I and set up as an independent company in the United States. Between the wars and during World War II, the company was led by George W. Merck, who oversaw America's germ-warfare research at Fort Detrick. Today, the US company has about 51,000 (S&P NetAdvantage) employees in 120 countries and 31 factories worldwide. It is one of the top 7 pharmaceutical companies worldwide, much larger than its German ancestor, which currently employs around 32,800 people in 62 countries.

In 1965 Merck acquired Charles E. Frosst Ltd. of Montreal (founded 1899) and created Merck-Frosst Canada Inc. as its Canadian subsidiary and pharmaceutical research facility. (In July 2010, Merck announced that this would be one of several operations to be closed.)^[4]

In 2005, CEO Raymond Gilmartin retired at the age of 64 following Merck's voluntary worldwide withdrawal of Vioxx. Former president of manufacturing Richard Clark was named CEO and President of the company.

On December 10, 2007, the company's share price reached a five-year high of $60.77. However, the share price of Merck since trended down, reaching an intraday low of $20.05 per share on March 9, 2009.

In November 2009, Merck announced that it would merge with competitor Schering-Plough in a US$41 billion deal.^[5][6][7][8] The purchase was a "reverse merger" in which Schering-Plough would be renamed Merck and continue as the surviving public corporation. The new company would operated under the trade name Merck in the United States and Canada and elsewhere under the trade name MSD.

On May 4, 2010, Merck announced its 2010 first quarter financial results. The company reported, among other things, that its financial results were affected both by the merger with Schering-Plough and tax charges related to the recently enacted health reform legislation. During the early months of 2010, Merck's stock began a slow slide downward. The stock peaked at 41.03 on January 20, 2010. By April 22, 2010, the stock had fallen to 33.77, a loss of 17.7%. This loss of stock is almost equal to the loss of 17.6% the American pharmaceutical company Pfizer had during this same time period. The slide is most likely caused by the speculation of passage and the eventual passage of the Health Care and Education Reconciliation Act of 2010 on March 21, 2010.

Corporate governance

As of November 3, 2009 (2009 -11-03)^[update] the members of the board of directors of Merck & Co. are: Richard T. Clark, Leslie A. Brun, Thomas R. Cech, Ph.D., Thomas H. Glocer, Steven F. Goldstone, William B. Harrison, Jr., Harry R. Jacobson, M.D., William N. Kelley, M.D., C. Robert Kidder, Rochelle B. Lazarus, Carlos E. Represas, Patricia F. Russo, Thomas E. Shenk, Ph.D., Anne M. Tatlock, Samuel O. Thier, M.D., Craig B. Thompson, M.D., Wendell P. Weeks, and Peter C. Wendell.^[9]

Products

Products on the market

• Antivenin - for the treatment of Black Widow Spider (Latrodectus mactans) bites
• Arcoxia (etoricoxib) - for the symptomatic treatment of osteoarthritis (not approved in the US, but approved and sold in Europe, Latin America, the Asia-Pacific region and Middle East/Northern Africa)
• Cancidas (caspofungin) - An echinocandins antifungal drug for treatment of Aspergillus and Candida.
• Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertension.
• Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.
• Crixivan (indinavir) – a protease inhibitor HIV medication.
• Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.
• Emend Injection (fosaprepitant dimeglumine) - an intravenous drug for nausea and vomiting caused by chemotherapy
• Emflex (Acemetacin) - a non-steroidal anti-inflammatory drug.
• Fosamax (alendronate) – osteoporosis medication.
• Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication.
• Gardasil (HPV vaccine) - a vaccine against human papillomavirus, a sexually transmitted disease.
• Isentress (raltegravir) - HIV integrase inhibitor.
• Janumet (sitagliptin/metformin) - an oral anti-diabetic drug for the treatment of type 2 diabetes.
• Januvia (sitagliptin) - a dipeptidyl peptidase-4 inhibitor for the treatment of diabetes
• Maxalt (rizatriptan) one of many triptans used to treat migraines.
• M-M-R II (MMR Vaccine) - immunization against measles, mumps and rubella.
• Pneumovax 23 (Pneumococcal polysaccharide vaccine) - a vaccine used to prevent Streptococcus pneumoniae infections such as pneumonia and septicaemia.
• Primaxin (imipenem with cilastatin) – a broad spectrum carbapenem antibiotic.
• Prinzide (lisinopril/hydrochlorothiazide) – anti-hypertensive combination of an ACE inhibitor and a diuretic.
• Propecia/Proscar (finasteride) – used for alopecia (male pattern baldness) and prostatic conditions.
• ProQuad (MMRV vaccine) - a vaccine for simultaneous vaccination against measles, mumps, rubella, and varicella in children.
• Recombivax HB (hepatitis B vaccine) - a vaccine that protects against hepatitis B.
• Rotateq - a vaccine to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children ages 0 to 12.
• Singulair (montelukast) – an asthma medication that blocks leukotrienes.
• Timoptic (timolol) - a non-selective beta-adrenergic receptor blocker used to treat high blood pressure and prevent heart attacks.
• Tredaptive (laropiprant/ER niacin) - a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia (not approved in the US, but approved in the European Union)
• Trusopt (dorzolamide) - reduces intraocular pressure in people with glaucoma or ocular hypertension.
• Vaqta (Hepatitis A vaccine) - a vaccine that protects against hepatitis A.
• Varivax (Varicella vaccine) - a vaccine that protects against chickenpox.
• Vytorin (ezetimibe/simvastatin) – a combination cholesterol-lowering preparation marketed in collaboration with Schering-Plough.
• Zetia (ezetimibe) - cholesterol absorption inhibitor which lowers LDL co marketed by Schering-Plough
• Zocor (simvastatin) – a cholesterol-lowering statin.
• Zolinza (vorinostat) - a histone deacetylase inhibitor for the treatment of cutaneous T cell lymphoma.
• Zostavax - a vaccine for prevention of shingles in adults older than 60 years of age.

Products from Schering-Plough

Products under development

• Anacetrapib
• Deforolimus
• Odanacatib
• Rolofylline
• Telcagepant
• An antidote for Statin toxicity (unnamed) ^[10]

Patient assistance programs

In the early 1950s, Merck & Co. was one of the first pharmaceutical companies to provide patient assistance programs in the U.S. to those unable to afford their medications.^[11] Currently, Merck & Co. offers 7 patient assistance programs, each with specific eligibility requirements.^[12][13]

Available programs

• Act Program For Emend
  • Emend (aprepitant)
• ACT Program For Zolinza
  • Zolinza (vorinostat)
• Merck Anti-Infective Hotline
  • Cancidas (caspofungin)
  • Invanz (ertapenem)
  • Primaxin (imipenem with cilastatin)
• Merck Patient Assistance Program
  • Cosopt (dorzolamide and timolol)
  • Cozaar/Hyzaar (losartan)
  • Fosamax (alendronate
  • Fosamax Plus D (alendronate/vitamin D)
  • Janumet (sitagliptin/metformin)
  • Januvia (sitagliptin)
  • Maxalt (rizatriptan)
  • Singulair (montelukast)
  • Timoptic (timolol)
  • Trusopt (dorzolamide)
• Merck Prescription Discount Program
  • Cosopt (dorzolamide and timolol)
  • Cozaar/Hyzaar (losartan)
  • Emend (aprepitant)
  • Fosamax (alendronate
  • Fosamax Plus D (alendronate/vitamin D)
  • Indocin (Indometacin)
  • Janumet (metformin)
  • Januvia (sitagliptin)
  • Maxalt (rizatriptan)
  • Singulair (montelukast)
  • Timoptic (timolol)
  • Trusopt (dorzolamide)
• Merck Vaccine Patient Assistance Program
  • Gardasil (HPV vaccine)
  • MMR Vaccine
  • Pneumovax 23 (Pneumococcal polysaccharide vaccine)
  • Recombivax HB (hepatitis B vaccine)
  • Vaqta (Hepatitis A vaccine)
  • Varivax (Varicella vaccine)
  • Zostavax
• SUPPORT Program For Crixivan
  • Crixivan (indinavir)

Vioxx

In 1999, the U.S. Food and Drug Administration (FDA) approved Vioxx (known generically as rofecoxib), a Merck product for treating arthritis. Vioxx was stronger than existing medications, while easier on the stomach than established anti-inflammatory drugs such as naproxen. Vioxx became one of the most prescribed drugs in history. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralised" or "discredited." "We may need to seek them out and destroy them where they live," wrote an employee. Also alleged were intimidation of researchers and impingement upon academic freedom.^[14]

Thereafter, studies by Merck and by others found an increased risk of heart attack associated with Vioxx use when compared with naproxen. There was no indication of this risk in the original placebo-controlled safety trials, and it was possible that the effect was more related to naproxen decreasing the risk of heart attacks than one of Vioxx increasing the risk. Merck adjusted the labeling of Vioxx to reflect possible cardiovascular risks in 2002.

On September 23, 2004, Merck received information about results from a clinical trial it was conducting that included findings of increased risk of heart attacks among Vioxx users who had been using the medication for over eighteen months.^[15] On September 28, 2004, Merck notified the FDA that it was voluntarily withdrawing Vioxx from the market, and it publicly announced the withdrawal on September 30. The FDA has since recommended that Vioxx be put back on the market, but with a more prominent warning regarding cardiovascular risks on its label.

On November 5, 2004 the medical journal The Lancet published the results of its analysis of the available studies. It concluded that "the unacceptable cardiovascular risks of Vioxx (rofecoxib) were evident as early as 2000..." ^[16] The journal's editors criticized Merck for having kept the drug on the market as long as it did before withdrawing it, and also criticized the FDA for its failure of regulatory oversight.

About 50,000 people have sued Merck claiming that they or their family members have suffered medical problems such as heart attacks or strokes after taking Vioxx.^[17] In 2005, Merck was found liable in the first case that went to trial and the plaintiff was awarded $253.4 million in damages; however, the judgement was subsequently reduced to $20 million and then, upon appeal, the verdict was reversed in 2008.^[17] In November 2007, Merck proposed to pay $4.85 billion to settle most of the pending Vioxx lawsuits.^[18][19] The settlement will require that claimants provide medical proof of having suffered a heart attack or a stroke and show they received at least 30 Vioxx pills. This proposed settlement is generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached as high as $50 billion. As of mid-2008, plaintiffs have prevailed in only three of the twenty cases that have reached juries, all with relatively small awards.^[17]

On May 20, 2008, Merck was found liable for using deceptive marketing tactics to promote Vioxx and 30 states will split the $58 million settlement. The amount is the largest multi-state settlement against a pharmaceutical company.^[20] All its new television pain-advertisements must be vetted by the Food and Drug Administration and changed or delayed upon request until 2018.^[21]

From 2002 through 2005 the Australian affiliate of Merck sponsored the eight issues of a medical journal, the Australasian Journal of Bone and Joint Medicine, published by Elsevier. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx.^[22]

Cordaptive

On September 4, 2007, Merck & Co. introduced the experimental drug Cordaptive, which can both raise HDL and lower LDL (combining an extended-release form of the B vitamin niacin with laropiprant, a novel compound intended to inhibit flushing or redness of the face). Cordaptive caused 18% drop in levels of LDL-C00, a 26% drop in triglycerides, and a 20% increase in HDL-C. Merck's cholesterol statin drug Zocor has seen sales plunge since its patent expired in 2006. In addition, Merck and partner Schering-Plough Corp. jointly market two other cholesterol drugs, Zetia and Vytorin.^[23]

On April 24, 2008, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the combination, to be marketed in Europe as Tredaptive.^[24]

On April 28, 2008, the FDA issued a "not approvable" letter for Cordaptive. In the FDA's letter, the agency rejected the proposed trade name CORDAPTIVE for MK-0524A.^[25][26]

The drug was later approved by the EMA on July 3, 2008.^[27][28]

Medicaid overbilling

A US Justice Department fraud investigation began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act.^[29] They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers.^[30] On February 7, 2008 Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The federal government received more than $360 million, and 49 states and Washington, DC, over $290 million. One whistleblower received a $68 million reward.^[29][31] Merck made the settlement without an admission of liability or wrongdoing.^[32]

Environmental record

Merck & Co. used methylene chloride which is an animal carcinogen and is on the Federal Environmental Protection Agency's list of pollutants. To get rid of this problem Merck chemists and engineers discovered a new way to manufacture products without using methylene chloride. The new way of creating chemicals seemed to have fewer negative environmental effects. Merck has also changed its equipment to protect the environment. Merck installed a computerized distributed control system that runs chemical reaction steps more effectively and has increased the process of operations by 50 percent. With the new machines, they have eliminated the need for the disposal and storage of harmful waste. The biological oxygen demand was reduced by 75% with a new process to help with water waste and other polluting waste.^[33] In 1991, Kelco, owned by Merck, was responsible for 1/3 of the VOC emission pollution in the San Diego area. The ground level ozone was causing health problems such as lung tissue damage and making the lungs easily vulnerable to harmful bacteria.^[34] In 1996 Merck paid 1.8 million dollars in a settlement that accused them of polluting the air. In addition, new machines were installed to cut the air pollution that the company's facilities were giving off. The new machines reduce the smog level emissions by 680,000 lb (310,000 kg) a year.^[35]

Isentress

Raltegravir (Isentress), Merck's HIV integrase inhibitor was unanimously recommended for accelerated approval by the FDA's Advisory Committee on September 5, 2007. Isentress works by acting on a specific enzyme in HIV, integrase, that allows the RNA from HIV to become part of human DNA in the replication process.^[36] Isentress was approved by the FDA on October 12, 2007.^[37]

Singulair

The FDA is looking into a link between the Merck drug Singulair, suicide and other psychological side effects, and is conducting research to see if Singulair should be reviewed further. Singulair works on blocking the Leukotriene pathway in both Asthma and Allergic Rhinitis.^[38]

See also

• Merck family
• Merck headquarters

References

External links

• About Merck & Co.
• The Merck Manuals
• Yahoo! - Merck & Co., Inc. Company Profile
• About Merck KGaA
• History of Merck
• Information about first lawsuit against Merck from Yahoo! Finance
• NEJM -Failing the Public Health — Rofecoxib, Merck, and the FDA
• Merck Frosst Canada
• Your Health Now
• Merck & Co. Patient Assistance Programs
• Peggy Peck (2008-10-22). "Economic Slowdown Sees Job Cuts at Merck and Drop in Prescription Drug Sales". MedPage Today. http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/11410. Retrieved 2008-10-22. 

Merck & Co., Inc. Corporate directors: Richard Clark · Johnnetta Cole · William Harrison · William Kelley · Rochelle Lazarus · Thomas Shenk · Anne Tatlock · Samuel Thier · Wendell Weeks · Peter Wendell Products: Alendronate · Aprepitant · Ertapenem · Ezetimibe · Ezetimibe/simvastatin · Finasteride · Fosaprepitant · Indinavir · Losartan · Lovastatin · Montelukast · Raltegravir · Rizatriptan · Rofecoxib · Simvastatin · Sitagliptin · Vorinostat Publications: The Merck Manuals (Index · Manual · Veterinary · Geriatrics) Annual Revenue: $22.9 billion USD (2% FY 2004) · Employees: 63,000 · Stock Symbol: NYSE: MRK · Website: www.merck.com